SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-095102
Filing Date
2024-08-12
Accepted
2024-08-12 09:05:20
Documents
65
Period of Report
2024-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q atos-20240630.htm   iXBRL 10-Q 1446005
2 EX-10.2 atos-ex10_2.htm EX-10.2 101021
3 EX-31.1 atos-ex31_1.htm EX-31.1 12879
4 EX-31.2 atos-ex31_2.htm EX-31.2 13156
5 EX-32.1 atos-ex32_1.htm EX-32.1 7740
6 EX-32.2 atos-ex32_2.htm EX-32.2 8695
7 GRAPHIC img96392089_0.jpg GRAPHIC 107028
  Complete submission text file 0000950170-24-095102.txt   6144825

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT atos-20240630.xsd EX-101.SCH 1048301
68 EXTRACTED XBRL INSTANCE DOCUMENT atos-20240630_htm.xml XML 725143
Mailing Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125
Business Address 10202 5TH AVENUE NE SUITE 200 SEATTLE WA 98125 206.588.0256
ATOSSA THERAPEUTICS, INC. (Filer) CIK: 0001488039 (see all company filings)

IRS No.: 264753208 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35610 | Film No.: 241195124
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)